Study: NCT04944771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.